Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) history spans 12 years, with the latest figure at -$0.03 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 167.47% year-over-year to -$0.03; the TTM value through Dec 2025 reached -$0.28, down 180.0%, while the annual FY2025 figure was -$0.28, 211.11% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.03 in Q4 2025 per LCTX's latest filing, up from -$0.13 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q4 2024 to a low of -$0.13 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.04, with a median of -$0.03 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 83.33% in 2021, then tumbled 550.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.05 in 2021, then soared by 40.0% to -$0.03 in 2022, then changed by 0.0% to -$0.03 in 2023, then skyrocketed by 66.67% to -$0.01 in 2024, then tumbled by 167.47% to -$0.03 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's EPS (Weighted Average and Diluted) are -$0.03 (Q4 2025), -$0.13 (Q3 2025), and -$0.13 (Q2 2025).